Premium
Long‐term salvage treatment by cyclosporin in refractory autoimmune haematological disorders
Author(s) -
Emilia Giovanni,
Messora Carlo,
Longo Giuseppe,
Bertesi Marcello
Publication year - 1996
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1996.4871026.x
Subject(s) - medicine , refractory (planetary science) , salvage therapy , evans syndrome , thrombocytopenic purpura , autoimmune thrombocytopenia , hematology , autoimmune hemolytic anemia , gastroenterology , chemotherapy , immunology , anemia , platelet , physics , astrobiology
We report on long‐term treatment (13–62 months) with cyclosporin A (CyA) in eight patients with autoimmune haematological disorders, resistant to all usual therapies. Three patients had an autoimmune haemolytic anaemia (AHA); four an idiopathic thrombocytopenic purpura (ITP), and one an Evans syndrome. All patients were responsive: six achieved complete remission and two partial remission. The side‐effects were moderate and transient. The majority of surviving patients remain dependent on continued drug administration. The CyA appears to be recommendable as a salvage treatment in life‐threatening, resistant autoimmune haematological diseases.